Purdie D W, Hay A, Abbas S K
Department of Obstetrics & Gynaecology, University of Leeds.
J R Soc Med. 1987 Nov;80(11):681-2. doi: 10.1177/014107688708001107.
The effects of danazol on calcium homeostasis in normal postmenopausal women was examined in a 14-day study utilizing a dosage of 800 mg per day. Danazol caused significant falls in plasma ionized calcium and in the fasting urinary calcium/creatinine ratio, indicating inhibition of bone resorption. Retention of phosphate was also observed as expected with this anabolic agent. The plasma total alkaline phosphatase was also depressed by the drug, which had no effect on hepatocellular function as measured by plasma AST. Certain effects induced by treatment with danazol were still apparent two weeks after cessation of treatment. The drug was well tolerated and androgenic side effects were not seen. It is suggested that the minimal dose regimen of danazol which exerts a calcium-sharing effect should be identified, and that this regimen should be considered for use in a prospective study of the effects of danazol on bone mineral content in the postmenopause.
在一项为期14天、每天服用800毫克达那唑的研究中，检测了达那唑对正常绝经后女性钙稳态的影响。达那唑导致血浆离子钙和空腹尿钙/肌酐比值显著下降，表明对骨吸收有抑制作用。正如这种同化激素所预期的那样，还观察到了磷酸盐潴留。该药物还使血浆总碱性磷酸酶降低，而对通过血浆谷草转氨酶测量的肝细胞功能没有影响。在停药两周后，达那唑治疗引起的某些效应仍然明显。该药物耐受性良好，未观察到雄激素副作用。建议确定发挥钙共享效应的达那唑最小剂量方案，并应考虑在一项关于达那唑对绝经后骨矿物质含量影响的前瞻性研究中使用该方案。
